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ABSTRACT 
Sputum induction by inhalation of hypertonic saline has been used for more than 
15 years. It has become one of the most intriguing methods to study airway inflammation. 
It is the only direct, non-invasive method for measuring airway inflammation indices. 
Sputum induction has been used in the diagnosis of many respiratory illnesses including 
asthma, chronic pulmonary obstructive disease, tuberculosis, chronic cough, lung cancer 
and Pneumocystis Carinii on patients who are unable to produce sputum spontaneously. 
There are currently many different methods used worldwide to induce sputum, but there 
is a lack of one generally accepted “gold standard” method. 
The proposed protocols for sputum induction proved to be safe, simple and 
produced satisfactory amount of expectorate. However, it did not contain enough cells 
from the lower respiratory tract and was contaminated by squamous cells when compared 
to another method based on the work of F. E. Hargreave. 
Investigation demonstrated that the use of impulse oscillometry, which requires 
no effort from patients, needs further research with larger study samples before it could 
be used instead of spirometry to evaluate airway obstruction. 
Initial methylene blue stain of the fresh expectorate smear was shown to be useful 
tool for identifying grossly contaminated sputum samples by squamous epithelial cells. 
Our first study group included 20 volunteers in good health. Sputum was induced by 
inhalation of 3% saline mist created by ultrasonic nebulizer at maximum output (4 
ml/min). Sputum induction intervals lasted 4-5 minutes with cumulative duration of 
induction about 4-15 minutes which was tolerated well. Lung function was evaluated for 
obstruction at baseline and every 5 minutes with spirometry and impulse oscillometry. 
The whole expectorated sample was processed and slides were stained with HEMA 3 
stain. With this method we were able to collect a mean of 6.1 ml expectorate. The mean 
total cell count was 804 000 with high proportion of squamous cells.  
The second study group included 5 volunteers in good health. This method 
utilized 3%, 4% and 5% saline mist for inhalation, 7 minutes each. Ultrasonic nebulizer 
was set at low output of 0.9 ml/min. This procedure was also tolerated well without major 
adverse effects. Lung function was evaluated at baseline and every 7 minutes for 
obstruction. Only dense portions of expectorate were selected and processed. Slides were 
stained with Wright stain. This method produced much more total cells with a mean of 3 
385 000 per gram of sputum which came from the lower airways and were not 
contaminated by squamous cells.  
The second method was far superior producing adequate sputum sample with 
cells from the lower airways and minimal squamous cell contamination and will be used 
in our Breath Lab.
1Introduction
       The purpose of sputum induction is to obtain an adequate amount of secretions from 
lower airways in subjects who are unable to produce sputum spontaneously and study the 
airway inflammation in asthma and other respiratory disorders2. For more than 15 years, 
sputum induction by inhalation of hypertonic saline has become one of the most widely 
used methods for studying a number of airway inflammatory conditions1. The mechanism 
by which inhalation of hypertonic saline induces sputum is not clear, but it has been 
hypothesized by researchers that the increased osmolarity also increases vascular 
permeability in bronchial mucosa2.  The study of cells and mediators in airway secretions 
from patients with pulmonary diseases has been performed in samples of spontaneously 
expectorated sputum on the fluid obtained by bronchoscopy and lavage4. These sampling 
methods are both limited in their applicability. Bronchoscopy can only be employed on 
patients who are well enough to tolerate the procedure. Bronchoscopy cannot easily be 
applied repeatedly to study inflammatory changes in airway secretions over short periods 
of time9. Sputum induction by inhalation of hypertonic saline has been suggested as the 
only direct, relatively non to invasive, and safe method for studying airway inflammation 
indices6.
       Spirometry involves measurements of a subject’s lung flow rates through a forceful 
exhalation to evaluate obstructive lung deficits. However, many debilitated patients are 
unable to perform forceful exhalation maneuvers. 
       In contrast, impulse oscillometry uses a pseudorandom noise signal generated in a 
normal tidal breathing air column. Advanced digital signal analysis techniques are used 
to derive respiratory parameters from air column pressure and flow data. These 
techniques allow localization of airway obstruction to distal or proximal airways40.
Advantages of impulse oscillometry are:  
1. It allows determination of lung characteristics during one minute of normal tidal 
breathing.
2. It requires practically no patient effort, which makes it especially useful for 
geriatric, pediatric, and occupational medicine subjects. 
3. It allows localization of airway obstruction to distal or proximal airways. 
            The purpose of initially using a methylene blue stain in this study is to identify grossly 
contaminated (by squamous cells) sputum samples. The advantage of initial methylene 
blue stain is its use as a quick and simple method for evaluation of sputum sample 
adequacy based on epithelial cell contamination before sending it to the laboratory. 
     The aims of this study were to: 
1. Propose a protocol for sputum induction based on previous research and compare 
it with another method in use based on the work of F.E. Hargreave,  
2. Obtain FEV1 values with conventional spirometry and compare those to values 
obtained with impulse oscillometry,  
3. Evaluate sputum sample adequacy based on squamous cell contamination by 
using the initial methylene blue staining method.  
2Review of the Literature 
       Sputum (also phlegm) definition: expectorated lower respiratory secretions49.
History
       Hippocrates described sputum as one of the four essential “humours” of the body1.
Bronchial secretions from the respiratory epithelium and submucosal glands, together 
with inflammatory cells that have migrated from the blood, are found in sputum50.
Gollasch found eosinophilic leukocytes in sputum from asthmatic patients over a century 
ago52. Expectorate from asthmatic patients occasionally demonstrates clusters formed by 
eosinophiles: so to called Charcot to Leyden crystals51. Curschman demonstrated clusters 
of shed epithelial cells in acute asthma in 188553. He also noted the presence of 
corkscrew to shaped twists of condensed mucus (Curschman`s spirals)53. The clusters of 
epithelial cells were later called Creola`s bodies54. From the 1950s to 1980s, sputum was 
analyzed microscopically, and fluid phase components were measured  to diagnose 
asthma and chronic bronchitis, and to assess disease severity1. In the 1950s, sputum 
testing was developed in connection with the diagnosis of lung cancer and tuberculosis1.
       Because many  patients were unable to provide sputum samples spontaneously, some 
were asked to inhale hypertonic saline to induce sputum. In relation to asthma, 
international interest in sputum testing arose after it was observed that epithelial damage 
and inflammatory changes are present even in early to stage asthma55.
       In 1964, Cleland identified dithiothreitol (DTT) which could reduce and split 
mucoprotein disulfide bonds56.
       In 1965, Shah and Dye showed that treatment with DTT allowed dispersion of 
sputum before processing of smears57. Since the 1980s, sputum induction by inhalation of 
hypertonic saline has been successfully used for diagnosing Pneumocystis Carinii 
pneumonia in patients infected with HIV4.
        In 1992, Pin et al. induced sputum production with the help of hypertonic saline to 
allow determination of eosinophilic inflammation in asthmatic patients15.
Induced Sputum 
       Production of the sputum is induced with inhalation of hypertonic saline mist to 
collect adequate samples of secretions from the lower airways. The induced sputum 
allows researchers to study airway changes caused by diseases in patients who are unable 
to produce sputum spontaneously. 
Studies have demonstrated that inhalation of isotonic or hypertonic saline 
solutions, via an ultrasonic nebulizer, can induce production of small amounts of 
secretions from the airways2. The mechanism of this process is not fully understood. It is 
hypothesized by researchers that increased osmolarity of bronchial lining fluid will 
3increase vascular permeability in the bronchial mucosa and production of mucus by 
submucosal glands2.
Induced sputum advantages compared to bronchoscopy include the following: 
1. its relatively non to invasive nature;
2. samples are obtained  from several proximal airways;  
3. it can be performed  repeatedly;  
4. it is safe in cases of severe disease;
5. there is no need for expensive equipment and; 
6. large patient populations can be studied1.
 Induced sputum disadvantages compared to bronchoscopy include: 
1. the risk of bronchoconstriction which increases with saline concentration (0.9% 
saline concentration is the safest and is used for high risk patients, 7% saline is the most 
dangerous);
2. the success rate is only about 80%;
3. the processing methods are laborious and;  
4. the results not available immediately1.
Clinical Applications 
                                                             Asthma 
       Asthma is considered a chronic inflammatory airway disease in which mast cells, 
eosinophiles and T lymphocytes play important roles1. The inflammation causes recurrent 
episodes of wheezing, shortness of breath, chest tightness, and cough, especially at night. 
The symptoms are associated with intermittent airflow limitation, which is reversible. 
Chronic airway inflammation also results in increased airway responsiveness to various 
stimuli (NHLBI/WHO 1995). This condition is commonly associated with sputum 
eosinophilia (>3%)5. There is some evidence that there is an increase of eosinophiles in 
sputum during workplace exposure in subjects with occupational asthma4. The validity of 
high sputum eosinophilia has shown to be better than pulmonary function tests variation 
and bronchodilator response at making the diagnosis of asthma5.
       The sputum fluid phase allows us to measure eosinophil cationic protein, some 
cytokines, and histamine5. The study of sputum inflammation indices would help us to 
understand better the complex relationships between inflammatory cells, mediators, 
cytokine mechanisms in asthma and enables us to monitor the condition and maybe 
clarify the diagnosis4. Assessing airway inflammation by studying sputum could also be 
used for evaluation of the effects of drugs on asthmatic airway inflammation1.
Chronic Obstructive Pulmonary Disease 
       Chronic obstructive pulmonary disease is characterized by the presence of  airflow 
obstruction which is associated with chronic bronchitis or emphysema1. The airway 
obstruction tends to be progressive and irreversible. Cigarette smoking is the main culprit 
in its etiology. The pathophysiology of chronic obstructive pulmonary disease is an 
4inflammatory disorder which is characterized by neutrophilic inflammation with the 
presence of macrophages and lymphocytes on airway tissue4. Marked sputum 
neutrophilia is very characteristic to chronic obstructive pulmonary disease1.
Bronchoscopic procedures are often not possible due to the condition severity and sputum 
induction becomes useful tool for pathophysiology studies4. The sputum neutrophil count 
is usually high. It can be correlated with a reduction of forced expiratory volume in one 
second and the rate of decline in forced expiratory volume in one second4. Inhaled steroid 
treatment has been shown to reduce neutrophil count in induced sputum4.
Sputum eosinophilia in some patients with chronic obstructive pulmonary disease may 
predict those patients who will benefit from oral steroid therapy4.
                                                         Chronic cough 
       Sputum neutrophilia is demonstrated in patients with chronic cough, but up to 40% 
of subjects with chronic cough have sputum eosinophil counts of more than 3%4.
Some patients with chronic cough and normal lung function demonstrate eosinophilic 
bronchial inflammation1. Patients with chronic cough and sputum eosinophilia 
demonstrate an objective response to corticosteroid treatment, which results in fall of the 
sputum eosinophil count4. Chronic cough patients who have responded to treatment with 
corticosteroids have also shown to be similar to patients with asthma in relation of gene 
expression of some cytokines58.
                                                           Tuberculosis 
       The World Health Organization recommends the detection of acid to fast bacilli in 
the respiratory secretion samples as the initial approach to the diagnosis of tuberculosis59.
       Unfortunately, this method has low sensitivity and has no value in patients who are 
unable to produce sputum spontaneously4. The studies have shown that sputum induction 
proves to be a safe procedure with high diagnostic yield. Also, the procedure highly 
correlates with the results of fiber optic bronchoscopy for the diagnosis of TB in HIV to
seronegative and HIV to seropositive patients60. Sputum induction is considered an 
alternative approach to the diagnosis of sputum smear to negative TB60.
                                                       Cystic Fibrosis 
       Cystic fibrosis is an autosomal, recessive, hereditary disease which results in 
production of abnormal secretion from a variety of exocrine glands4. Lung involvement is 
manifested by recurrent infections with Pseudomonas Aeruginosa and Staphylococcus 
Aureus.
       Sputum induction is a relatively safe, noninvasive method of obtaining airway 
secretions from subjects with cystic fibrosis, especially those who are unable to produce 
sputum spontaneously4.
       Induced sputum provides an accurate measure of infection and inflammation in the 
lungs and appears to be comparable to spontaneously expectorated samples61.
       Induced sputum has demonstrated a higher number of viable cells and less squamous 
cell contamination4.
5                                                      Lung cancer 
       Sputum sample cytological examination has been shown to lead to lung cancer 
detection at an earlier stage. Unfortunately, the yield of this test is low4. Recent studies 
have demonstrated that adequate sputum samples will allow genetic analysis to be 
performed, which could prove to be a useful tool for cancer screening16.
                                                 Pneumocystis carinii 
       Pneumocystis carinii pneumonia is characterized by fever, shortness of breath, 
substernal tightness, and non to productive cough, and affects mainly immunosuppressed 
patients. Transbronchial biopsy and bronchoalveolar lavage are considered a “gold 
standard” in diagnosis of Pneumocystis carinii pneumonia,  but they result in some 
morbidity and are expensive. Induced sputum analysis was found to be a safe, sensitive, 
specific, rapid and low to cost technique for the diagnosis of Pneumocystis carinii 
pneumonia62.
                                 Induced sputum fluid to phase analysis 
       Sputum fluid to phase has shown to contain many more  mediators than 
broncoalveolar lavage5. Inflammatory mediators include cytokines, chemokines, 
granulocyte proteins, markers of vascular leakage, eicosanoids and proteases45.
       Markers of eosinophil activation include eosinophilic cationic protein (most 
cytotoxic), major basic protein, eosinophil protein X and eosinophil peroxidase63.
       Myeloperoxidase is a protein released from primary granules of neutrophils, and can 
serve as a marker of neutrophil activation. Human neutrophil lipokalin is another protein 
released from secondary neutrophil granules64.
Fluid to phase mediators can be assessed by Immuno- , Bio- , or Enzyme Assays4.
6Methods
       The  study subjects included 25 healthy, non-smoking adults between the ages of 19 
to 51 years old who were asked to volunteer for the study in the Breath Laboratory at the 
College of Public Health. IRB approval # 103292. Volunteer subjects were given 
information about the purpose of the study, elements of the procedure, possible risks, 
potential benefits, and alternatives to the study protocol.  All pertinent questions were 
answered, and relevant issues were discussed. When subjects demonstrated a full 
understanding of the study protocol and indicated a desire to proceed, they were required 
to sign an informed consent.   
After informed consent was obtained, subjects completed a Medical Screening 
Questionnaire and underwent a brief physical examination to assess their 
cardiopulmonary system.  All aspects of the protocol were completed in the presence of 
an advanced cardiac life support (ACLS) certified physician.  Following the 
questionnaire and physical exam, complete spirometry, including FEV1 was performed 
under ATS criteria39. Subjects were excluded from further study if their FEV1 was below 
60% of predicted, which is indicative of moderately severe bronchial obstruction38.
Following spirometry, subjects had their respiratory impedance measured with the Jaeger 
Impulse Oscillometer40, which uses a pseudorandom noise signal generated in the normal 
tidal breathing air column. Advanced digital signal analysis techniques are used to derive 
respiratory parameters from air column pressure and flow data, allowing localization of 
airway obstruction to the distal or proximal airways. 
The first study group of 20 subjects underwent sputum induction and processing 
by  proposed protocol and the rest of the 5 subjects followed the sputum induction and 
processing protocol based on F.E. Hargreave work. 
Proposed Sputum Induction Procedure and Processing Protocol: 
1) The subject should rinse out his/her mouth thoroughly with water and place the nose 
clip on the nose1,2.
2) Breathe tidally for 5 minutes while inhaling a 3% hypertonic saline mist generated by 
the (Devilbiss Ultra to Neb Large Volume Ultrasonic Nebulizer model 099HD) ultrasonic 
nebulizer (start with low out to put for about 10 seconds. Then gradually increase to 
maximum out to put of 4 ml/min to prevent cough)2,25.
3) Ask the subject to perform a maximal inhalation of 3% saline mist and to hold their 
breath for 5 seconds. Then exhale.  This was performed a total of 3 times12.
4) Following the final deep inhalation, the subject is to cover their mouth and cough 
deeply from the base of their chest12.
75) Collect the expectorated mucus in a 50 ml conical tube, with the goal of collecting at 
least 5ml2,12.
6) Perform the sputum collection procedure at least 3 times to maximize the quality and 
quantity of cells.  Typically, this will require 6 minutes per procedure, or a total of 20 to 
30 minutes until an adequate sample is obtained1,2.
7) Check the FEV1 again after each attempt to induce and collect sputum. Then compare 
to the best FEV1 from the baseline evaluation. If the FEV1 drops more than 20%, the 
study should be stopped. In addition, if the subject has an adverse symptom such as chest 
tightness, shortness of breath, chest pain, or if they wish to stop, no further testing should 
be done66,67.
8) Follow each spirometry by one maneuver of impulse oscillometry using the Jaeger  
IOS40.
Sputum Processing and Analysis: 
       Initial (before adding DTT) sputum smear staining by methylene blue stain was 
performed using 1% methylene blue aqueous solution (cover the smear with 1 to 2 drops 
of stain) for one minute (time is not critical, 30 seconds to 2 minutes will give you 
acceptable stain) after heat fixation (pass the slide 3 times over the Bunsen burner 
flame)36. Samples with fewer than 50% squamous cells in the field of view is considered 
adequate (use100x magnification)1.
1) Add an equal volume of freshly prepared DITHIOTHREITOL (DTT) 10% solution by 
adding 90ml of distilled, sterile water to 10ml of Sputolysin41 to preweighed entire 
expectorate28.
2) Aspirate the expectorate with a disposable pipette several times and then briefly agitate 
with a vortex mixer47.
3) Place the conical tube in a shaking water bath (Bransonic model 2510R with 40 kHz 
output) set at 22 degrees Celsius (may range from 22 to 37 degrees Celsius)28 bath for 15 
minutes, or until the mucus has dissolved, and the expectorate is a thin fluid.   
4) Filter the fluid through a 70 micron nylon mesh28.
5) Perform a manual, total cell count using a hemacytometer.   First, dilute 100 
microliters of cell suspension with an equal volume of 0.4 % Trypan blue.  Then, mix 
well and place a drop (~10 to 20 microliters) at each notch of the hemacytometer with a 
micropipette. First count squamous cells in large corner squares using 100 times 
magnification followed by total cell count. Count the total number of cells in the four, 1 
mm corner squares using 400x magnification and get the average.  Multiply the number 
of cells by 10 000 (the corner square has a volume of 0.0001 ml)30 and then multiply by a 
dilution factor of 4 to determine the number of cells per milliliter . 
86) Assess cell viability with the Trypan blue exclusion method.  Trypan blue stain was 
added to the cell suspension in the previous step. Viable cells will not stain with Trypan 
blue, while dead cells will stain dark blue37. Centrifugation is recommended at this point 
if interested in fluid phase measurements. Suggested centrifugation speeds have ranged 
from 300 to 1500g with 5 to 10 durations23.
7) Prepare the sample for the Cytospin28.  Depending on the previous manual cell count, 
the sample may need to be diluted with phosphate buffered saline (add equal amount of 
PBS to reduce the cell count to one half in one ml) or concentrated (after centrifugation re 
to suspend the cell pellet with half of the previous sample volume of BPS). Optimum 
number of cells for cytospin is 40 000 to 60 00028. The recommended cell suspension 
dilution is around 0.5 million cells per ml.  Transfer 0.1ml (appropriate dilution should 
produce monolayer of cells on the slide which will facilitate the identification of different 
cell types) of the cell suspension into a disposable cytochamber that plates the suspension 
onto a Thermo Shandon coated to slide.  This preparation is centrifuged in the Cytospin 
at 440 RPM for 6 minutes28.  Let the slides dry after centrifugation 34.
8) Stain using the HEMA 3 Stain set, which is comparable to Wright to Giemsa stain:   
A) Dip the prepared slide into the HEMA 3 Fixative Solution for 1 second, five 
individual times.  Allow the excess solution to drain prior to the next step.
B)  Dip the slide 3 to 5 times for one second each time in the Hema 3 Solution One. 
Allow the excess solution to drain prior to the next step. 
C)  Dip the slide 3 to 5 times for one second each time in the Hema 3 Solution Two. 
Allow the excess solution to drain prior to the next step. 
D) Rinse the slide with de to ionized water. 
E) Allow the excess water to dry.
9) Perform a differential cell count on the prepared slide under an oil immersion lens.   
There should be a minimum of 400 non to squamous cells32,35. Count 400 cells in the 
field of view at 400x magnification and report the proportion of cells counted.  Identify 
the following cell types 32.
Neutrophils: nucleus has 2 to 8 lobes, 10 to 12 micron diameter, nucleus stains purple, 
granules red to lilac and cytoplasm light pink. 
Figure 1: Neutrophil (35) 
9Eosinophils: nucleus bi to lobed, 12 to 15 micron diameter, nucleus stains dark blue, 
granules red to orange and the cytoplasm is medium blue. 
Figure 2: Eosinophil (35) 
Basophils: nucleus is bi to  or tri to lobed, 9 to 10 micron diameter, nucleus stains dark 
blue, granules dark purple and cytoplasm light blue. 
Figure 3: Basophil (35) 
Monocytes: (these will become macrophages) indented nucleus, 20 micrometer diameter,  
nucleus stains violet, and the cytoplasm is light blue. 
Figure 4: Monocyte (35) 
Lymphocytes: nucleus spheroid or ovoid, 6 to 8 or 8 to 12 micrometer diameter, nucleus
stain violet. 
Figure 5: Lymphocyte (35) 
Sputum Induction and Processing Protocol based on F.E. Hargreave work69:
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1) The subject should rinse out his/her mouth thoroughly with water and place the nose 
clip on the nose1,2.
2) Breathe tidally for 7 minutes while inhaling a 3% hypertonic saline mist generated by 
the (Devilbiss Ultra to Neb Large Volume Ultrasonic Nebulizer model 099HD) ultrasonic 
nebulizer at output of 0.9 ml/min.68,70
3) Measure FEV1 again using spirometry followed by three maneuvers of impulse 
oscillometry by the Jaeger IOS. If the FEV1 drops more than 20% compared to the best 
baseline value or troublesome symptoms such as chest tightness/pain, shortness of breath 
occur the procedure should be stopped. If fall in FEV1 is between 10% to 20% repeat 
previous inhalation. Also if the subject wishes to stop, no further testing should be 
done66,69.
4) Blow nose, rinse mouth, swallow water and expectorate sputum into Petri dish68,69.
5) Repeat this procedure with 4% and 5% saline68,69.
Processing:
1) Select dense portions (plugs) of expectorate which appear macroscopically free of 
salivary contamination (up to 1000 mg) using a straight blunted forceps and place them 
into 50 ml conical tube (if necessary using inverted microscope)68,69.
2) Weigh the selected sputum and add with pipette four times of the volume of freshly 
prepared DITHIOTHREITOL (DTT) 10% solution by adding 90ml of distilled, sterile 
water to 10ml of Sputolysin41,68,69.
2) Aspirate the expectorate with a disposable pipette several times. Then briefly agitate 
with a vortex mixer for 15 seconds47,69.
3) Rock on bench rocker for 15 minutes68,69.
4) Mix with equal volume to DTT of Dulbecco`s phosphate buffered saline (D to PBS)68
and continue on bench rocker for another 5 minutes. 
5) Filter the fluid through a 70 micron nylon mesh28,68,69.
6) Centrifuge at 790g for 10 minutes if interested in fluid phase components 
measurements. Aspirated supernatant should be stored at  to 70o of Celsius for later 
assays68,69.
7) Re to suspend cell pellet in a volume of D to PBS68,69.
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8) Perform a manual, total cell count using a hemacytometer.   First, dilute 100 
microliters of cell suspension with an equal volume of 0.4 % Trypan blue using pipette.  
Then, mix well and place a drop (~10 to 20 microliters) at each notch of the 
hemacytometer with a micropipette. Begin counting squamous cells in large corner 
squares using 100 times magnification, followed by total cell count. Count the total 
number of cells in the four, 1 mm, corner squares using 400x magnification and get the 
average.  Multiply the number of cells by 10,000 (the corner square has a volume of 
0.0001 ml)30. Finally, multiply by the dilution factor to determine the number of cells per 
milliliter. 
9) Assess cell viability with the Trypan blue exclusion method.  Trypan blue stain was 
added to the  cell suspension in the previous step. Viable cells will not stain with Trypan 
blue, while dead cells will stain dark blue37.
10) Prepare the sample for the Cytospin28.  Depending on the previous manual cell count, 
the sample may need to be diluted with phosphate buffered saline (add equal amount of 
PBS with pipette to reduce the cell count to one half in one ml) or concentrated (after 
centrifugation re to suspend the cell pellet with half of the previous sample volume of 
BPS). Optimum number of cells for cytospin is 40 000 to 75 00028,68. The recommended 
cell suspension dilution is around 1 million cells per ml.  Transfer 75 microliters 
(appropriate dilution should produce monolayer of cells on the slide which will facilitate 
the identification of different cell types) of the cell suspension with pipette into a 
disposable cytochamber that plates the suspension onto a Thermo Shandon coated to 
slide.  This preparation is centrifuged in the Cytospin at 450 RPM for 6 minutes28,68,69.
Let the slides dry after centrifugation 34.
11) Stain using the Wright`s stain69:
A) Dip slides in stain for 10 to 15 seconds. 
B) Dip slides in de to ionized water for 15 to 30 seconds. 
C) Rinse slides by dipping in de to ionized water for a few seconds and air dry.
12) Perform a differential cell count on the prepared slide under an oil immersion lens.   
There should be a minimum of 400 non to squamous cells32,35. Count 400 cells in the 
field of view at 400x magnification and report the proportion of cells counted.
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Results
        The first study population consisted of twenty, healthy, non-smoking, adult subjects 
(ten male and ten female). The age of the population ranged from 19 to 51 years with a 
mean age of 30.15 years. All subjects denied any major cardiopulmonary conditions. 
Health problems that were reported included Crohn disease, kidney stone, goiter, kidney 
transplant, high blood pressure, gout, mononucleosis, migraines and GERD. 
       Thirteen people underwent a single, four-minute, sputum induction interval, which 
produced a mean of 6.07 ml expectorate with range from 4.8 to 10 ml (extreme value of 
30 ml was excluded). 
       Two subjects underwent two, four-minute, sputum induction intervals, which 
produced a mean of 6.15 ml of expectorate (6 and 6.3 ml). 
       The last five subjects underwent three, five-minute, sputum induction intervals, 
which produced a mean of 6.19 ml of expectorate with range from 5 to 7.65 ml. 
       For the whole study population, the mean total cell count was 804 100 cells per ml, 
with range from 310 000 to 3 690 000 cells per ml. The mean proportion of squamous 
cells was 38% ranging from 3% to 81%. 
       Thirteen subjects who underwent one, four-minute, sputum induction interval had a 
mean total cell count of 946 000 cells per ml with range from 360 000 to 3 690 000 cells 
per ml and mean proportion of squamous cells of 37% (3% to 67%). 
       Two subjects who underwent two, four-minute, sputum induction intervals had a 
mean total cell count of 705 000 cells per ml (310 000 and 1 100 00) with the mean 
proportion of squamous cells of 57% (81% and 33%). 
       Five subjects who underwent three, five-minute, sputum induction intervals had a 
mean total cell count of 694 400 per ml (360 000 to 1 100 000) with the mean proportion 
of squamous cells of 34% (25% to 57%). 
       Subject 37 who underwent three, five-minute, intervals of sputum induction 
produced 1.5 ml of expectorate after the first interval which contained 400 000 cells per 
ml (15% squamous cells), 3.5 ml of expectorate after the second session, which contained 
440 000 cells per ml (82% squamous cells), and 2.5 ml of expectorate after the third 
session containing 240 000 cells per milliliter (75% squamous cells). 
       Based on FEV1 and impulse oscillometry measurements, a correlation coefficient 
was calculated for the thirteen subjects who underwent one, four-minute, sputum 
induction interval which demonstrated value of  to 0.196 at p=0.52. Two subjects who 
underwent two, four-minute, intervals of sputum induction had correlation coefficient of
to 1.000. A p value was not reported by the SAS software due to small sample size of this 
group. The last five subjects who underwent three, five-minute, intervals of sputum 
induction demonstrated correlation coefficient of  to 0.622 at p=0.26. 
       Freshly expectorated sputum smears were prepared on the slides and stained by 
methylene blue stain, which demonstrated more than 50% squamous cell predominance 
in the field of view for subjects 23,25,28,37 and 26. Accordingly, their counted squamous 
cells proportions were 81%, 67%, 58%, 79% and 54%. It is very subjective and hard to 
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evaluate, but subjects 29.24,25,31,35,22,21,36 and 38 seem to have squamous cell 
proportions seen on slides in the field of view around 50%. Their calculated squamous 
cell percentages were: 42%,42%,40%,38%,35%,33%,33%,32% and 31%. The rest of the 
subjects 40,33,39,34,30 and 32 seem to have less than 50% of squamous cells in the field 
of view.  According calculated percentages: 26%,26%,25%,23%,21% and 3%. 
       Cytospin slides demonstrated mostly squamous epithelial cells, which made it 
impossible to perform differential cell count. 
       The second study population consisted of 5 healthy, non-smoking, adult males. The 
ages ranged from 20 to 46 years with a mean age of 34.4 years. The mean total cell count 
was 3 385 000 cells per ml with range from 1 150 00 to 6 250 000 cells per ml. The mean 
proportion of squamous cells was 11.2% ranging from 8% to 19%.  
        Cells viability ranged from 53% to 73% with a mean of 66.2%. Differential cell 
counts demonstrated a mean of 0.4% of Eosinophils, 19.2% Neutrophiles, 79.1% of 
Macrophages and 1.3% of Lymphocytes. 
         Based on FEV1 and impulse oscillometry measurements a correlation coefficient 
was calculated, which demonstrated no correlation. 
       The data was analyzed using SAS version 9.1 statistical software. 
14
Table 1: First Study Population Characteristics 
Subject Gender Age
Expectorate
Volume
After
4 minutes
(ml)
Expectorate 
Volume 
After 8 
minutes 
(ml) 
Expectorate 
Volume 
After 15 
minutes 
(ml) 
Total Cell 
Count per 
Mililiter 
% of 
Squamous 
cells
21 M 33 . 6.00 . 1100000 33 
22 F 51 7.50 . . 1320000 33 
23 F 51 . 6.30 . 310000 81 
24 M 27 10.00 . . 360000 42 
25 M 19 7.00 . . 720000 40 
26 M 19 5.00 . . 980000 54 
27 M 34 5.00 . . 450000 67 
28 M 20 4.80 . . 1090000 58 
29 M 22 4.90 . . 690000 42 
30 F 41 9.00 . . 610000 21 
31 M 20 5.00 . . 800000 38 
32 F 23 4.90 . . 3690000 3 
33 M 46 30.00 . . 380000 26 
34 F 24 4.80 . . 440000 23 
35 M 46 4.90 . . 770000 35 
36 F 34 . . 5.00 530000 32 
37 F 23 . . 7.50 360000 57 
38 F 23 . . 5.00 1050000 31 
39 F 22 . . 5.80 432000 25 
40 F 25 . . 7.70 1100000 26 
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Table 2: Spirometry Measurements (FEV1 in Liters) 
Subject Predicted Baseline 1st Induction 
2nd 
Induction 
3rd Induction 
21 4.51 5.04 4.87 5.06 . 
22 2.67 3.23 2.89 . . 
23 2.75 3.73 3.79 3.84 . 
24 4.69 3.62 3.82 . . 
25 4.58 4.36 4.34 . . 
26 4.58 4.22 4.62 . . 
27 4.32 4 3.43 . . 
28 3.85 3.68 3.31 . . 
29 4.38 3.37 2.75 . . 
30 3.26 2.73 3 . . 
31 3.99 4.1 3.86 . . 
32 3.96 3 2.98 . . 
33 3.97 4.74 4.73 . . 
34 2.9 2.93 2.87 . . 
35 3.97 3.93 4.18 . . 
36 3.19 3.11 3.05 3.01 3.05 
37 3.39 3.39 3.07 3.07 3.04 
38 3.23 3.58 3.44 3.51 3.39 
39 3.33 3.07 2.9 2.92 2.9 
40 3.67 2.95 2.9 2.73 2.81 
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Table 3: Spirometry Measurements to Percentages of Predicted Values  
Subject
% of 
Predicted 
Baseline 
% of 
Predicted 
1st 
Induction 
% of 
Predicted 
2nd 
Induction 
% of 
Predicted 
3rd 
Induction 
21 111.6 107.9 112.1 . 
22 121 108.1 . . 
23 135.8 137.7 139.6 . 
24 77.1 81.5 . . 
25 95.3 94.7 . . 
26 92.1 100.9 . . 
27 92.6 79.4 . . 
28 95.5 85.8 . . 
29 76.9 62.8 . . 
30 83.8 91.8 . . 
31 102.8 96.8 . . 
32 75.8 75.3 . . 
33 119.6 119.2 . . 
34 101.1 99.1 . . 
35 99.2 105.3 . . 
36 97.5 95.5 94.3 95.7 
37 100.1 90.6 90.6 89.8 
38 110.8 106.4 108.4 104.9 
39 92 86.9 87.6 87.2 
40 80.4 79.2 74.6 76.7 
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Table 4: Impulse Oscillometry Measurements (R5) 
Subject Predicted Baseline 1st Induction 2nd Induction 3rd Induction 
21 2.75 3.36 3.84 4.14 . 
22 3.87 4.32 4.3 . . 
23 3.87 5.28 4.44 4.48 . 
24 2.69 2.71 3.47 . . 
25 2.6 3.62 3.64 . . 
26 2.6 4 3.52 . . 
27 2.76 2.46 2.15 . . 
28 2.62 2.79 3.01 . . 
29 2.63 2.85 2.82 . . 
30 3.7 8.67 9.16 . . 
31 2.61 3.46 4.37 . . 
32 2.96 4.47 3.69 . . 
33 2.9 3.66 3.94 . . 
34 3.41 5.34 4.35 . . 
35 2.9 4.07 3.73 . . 
36 3.57 5.17 4.67 4.79 5.26 
37 3.4 3.02 3.1 3.19 2.9 
38 3.4 2.73 3.16 2.82 3.16 
39 3.38 4.73 4.97 4.86 4.97 
40 3.43 4.56 4.93 5.28 4.84 
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Table 5: Impulse Oscillometry Measurements to Percentages of Predicted Values (R5) 
Subject
% of 
Predicted 
Baseline 
% of 
Predicted 
1st 
Induction 
% of 
Predicted 
2nd 
Induction 
% of 
Predicted 
3rd 
Induction 
21 122.2 139.4 150.4 . 
22 111.7 111 . . 
23 136.4 114.8 115.6 . 
24 101.1 129.3 . . 
25 139.4 140.2 . . 
26 154.2 136 . . 
27 89 78 . . 
28 106.8 115.2 . . 
29 108.4 107.1 . . 
30 234.2 247.5 . . 
31 132.6 167.6 . . 
32 150.9 124.6 . . 
33 126.4 136 . . 
34 156.4 127.5 . . 
35 140.6 128.8 . . 
36 144.9 131.1 134.4 147.7 
37 89.1 91.2 93.8 85.4 
38 80.3 93.2 83 93.5 
39 139.9 147 143.8 147.3 
40 133.1 143.8 154 141 
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Table 6: Spirometry Measurements to Percentages and Differences of Change from 
Baseline Values (FEV1 in Liters) 
Differences  Percentages  
Subject
1st  
Induction  
to  
Baseline 
2nd 
Induction 
to Baseline 
3rd 
Induction 
to Baseline 
1st
 Induction  
to 
 Baseline 
2nd  
Induction  
to 
 Baseline 
3rd 
Induction  
to  
Baseline 
21 -0.17 0.02 .  -3.373 0.39683 .
22 -0.34 . .  -10.5263 . .
23 0.06 0.11 . 1.6086 2.94906 .
24 0.2 . . 5.5249 . .
25 -0.02 . .  -0.4587 . .
26 0.4 . . 9.4787 . .
27 -0.57 . . -14.25 . .
28  -0.37 . .  -10.0543 . .
29 -0.62 . . -18.3976 . .
30 0.27 . . 9.8901 . .
31 -0.24 . . -5.8537 . .
32  -0.02 . . -0.6667 . .
33 -0.01 . . -0.211 . .
34  -0.06 . . -2.0478 . .
35 0.25 . . 6.3613 . .
36 -0.06 -0.1 -0.06 -1.9293  -3.21543 -1.9293 
37 -0.32 -0.32 -0.35 -9.4395 -9.43953 -10.3245 
38 -0.14 -0.07 -0.19 -3.9106 -1.95531 -5.3073 
39 -0.17 -0.15 -0.17 -5.5375 -4.88599 -5.5375 
40 -0.05 -0.22 -0.14 -1.6949 -7.45763 -4.7458 
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Table 7: Impulse Oscillometry Measurements to Percentages and Differences of Change 
from Baseline Values  
Subject 1st Induction to Baseline
2nd Induction 
21 0.48 0.78 . 14.2857 23.2143 .
22 -0.02 . . -0.463 . .
23 -0.84 -0.8 . -15.9091 -15.1515 .
24 0.76 . . 28.0443 . .
25 0.02 . . 0.5525 . .
26 -0.48 . .  to 12 . .
27 -0.31 . . -12.6016 . .
28 0.22 . . 7.8853 . .
29 -0.03 . . -1.0526 . .
30 0.49 . . 5.6517 . .
31 0.91 . . 26.3006 . .
32 -0.78 . . -17.4497 . .
33 0.28 . . 7.6503 . .
34 -0.99 . . -18.5393 . .
35 -0.34 . . -8.3538 . .
36 -0.5 -0.38 0.09 -9.6712 -7.3501 1.7408 
37 0.08 0.17  -0.12 2.649 5.6291 -3.9735 
38 0.43 0.09 0.43 15.7509 3.2967 15.7509 
39 0.24 0.13 0.24 5.074 2.7484 5.074 
40 0.37 0.72 0.28 8.114 15.7895 6.1404
PercentagesDifferences
3rd Induction
to Baselineto Baseline to Baseline
1st Induction 2nd Induction
to Baseline
3rd Induction
to Baseline
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Table 8: Impulse Oscillometry Measurements (R20) 
Subject Predicted Baseline 
1st 
Induction 
2nd 
Induction 
3rd 
Induction 
21 2.34 2.73 3.26 3.25 . 
22 3.26 3.67 3.63 . . 
23 3.26 4.63 3.97 3.88 . 
24 2.28 2.25 2.89 . . 
25 2.19 2.71 2.64 . . 
26 2.19 3.56 3.25 . . 
27 . . . . . 
28 . . . . . 
29 . . . . . 
30 3.08 5.54 5.36 . . 
31 2.2 2.96 3.75 . . 
32 2.55 4.11 3.37 . . 
33 2.49 2.98 3.3 . . 
34 2.8 4 3.42 . . 
35 2.49 3.91 3.44 . . 
36 2.95 4.11 3.74 3.92 4.25 
37 2.78 2.55 2.34 2.67 2.58 
38 2.78 2.83 3.07 2.96 3.01 
39 2.76 4.59 4.72 4.68 4.86 
40 2.81 4.01 4.23 4.29 4.23 
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Table 9: Correlation Coefficients for Spirometry (FEV1) and Impulse Oscillometry (R5) 
Measurements of Percentages of Change of 1st Induction from Baseline Values (SAS 
Output)
Pearson Correlation Coefficients, N = 20  
Prob > |r| under H0: Rho=0 
FEV1
% change 
1st Induction to Baseline 
R5 
% change 
1st Induction to Baseline 
FEV1
% change 
1st Induction to Baseline 
1.00000 -0.02410 
0.9197 
R5 
% change 
1st Induction to Baseline 
-0.02410 
0.9197 
1.00000 
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Table 10: Correlation Coefficients for Spirometry (FEV1) and Impulse Oscillometry (R5) 
Measurements of Percentages of Change of 2nd Induction from Baseline Values (SAS 
Output)
Pearson Correlation Coefficients, N = 7  
Prob > |r| under H0: Rho=0 
FEV1
% change 
2nd Induction to Baseline 
R5 
% change 
2nd Induction to Baseline 
FEV1
% change 
2nd Induction to Baseline 
1.00000 -0.32009 
0.4840 
R5 
% change 
2nd Induction to Baseline 
-0.32009 
0.4840 
1.00000 
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Table 11: Correlation Coefficients for Spirometry (FEV1) and Impulse Oscillometry (R5) 
Measurements of Percentages of Change of 3rd Induction from Baseline Values (SAS 
Output)
Pearson Correlation Coefficients, N = 5  
Prob > |r| under H0: Rho=0 
FEV1
% change 
3rd Induction to Baseline 
R5 
% change 
3rd Induction to Baseline 
FEV1
% change 
3rd Induction to Baseline 
1.00000 0.39609 
0.5092 
R5 
% change 
3rd Induction to Baseline 
0.39609 
0.5092 
1.00000 
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Table 12: Slide Estimates and Counted Percentage of Squamous Cells 
Slide Estimation Counted Percentage 
      of  Squamous Cells % 
Subject < 50% 
Around 
50% (Undetermined) 
>50%  
23 . . y 81 
27 . . y 67 
28 . . y 58 
37 . . y 57 
26 . . y 54 
29 . y . 42 
24 . y . 42 
25 . y . 40 
31 . y . 38 
35 . y . 35 
22 . y . 33 
21 . y . 33 
36 . y . 32 
38 . y . 31 
40 y . . 26 
33 y . . 26 
39 y . . 25 
34 y . . 23 
30 y . . 21 
32 y . . 3 
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Table 13: Second Study Group Population Characteristics
Subject Gender Age 
Total 
Cell
Count/ 
gram of 
sputum 
% of 
Squamous 
Cells
% of 
Viability 
41 M 34 1,150,000 11 65 
42 M 41 1,625,000 19 53 
43 M 46 5,600,000 5 71 
44 M 31 2,300,000 13 69 
45 M 20 6,250,000 8 73 
Table 14: Spirometry and Impulse Oscillometry Measurements – Percentages of 
Predicted Values 
   Spirometry     IOS  to  R5/R20 
Subject Baseline 
% of 
Predicted 
 1st 
Induction 
% of 
Predicted 
2nd 
Induction 
% of 
Predicted 
3rd 
Induction Baseline 
199.3/197.9
131.2/125.0
% of 
Predicted 
 1st 
Induction 
% of 
Predicted 
2nd 
Induction
45 94.8 93.1 91.5 89.2 112.8/113.9 137.9/140.6135.1/134.8
44 104.8 103.8 102.9 102.5 187.9/185.8 251.3/259.7  169.1/179.3
161.4/187.043 107.9 105 94.8 96.7 140.7/155.0 141.0/154.0 117.6/134.1
42 68.7 60.4 53.1 55.2 203.6/168.6 203.3/144.4 228.8/162.2 186.8/148.1
41 131.1 129.8 130 124.7 93.0/98.9 103.3/103.7 92.6/101.1 89.1/93.3
% of 
Predicted 
3rd
Induction
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Table 15: Impulse Oscillometry and Spirometry Measurements  to  Percentages 
Differences of Change from Baseline Values  
IOS  to  R5 Spirometry 
Subject
% of Predicted 
1st Induction 
% of Predicted 
2nd Induction 
%of Predicted 
3rd Induction 
% of Predicted 
1st Induction 
% of Predicted 
2nd Induction 
%of Predicted 
3rd Induction 
41 10.3 -0.4 -3.9  -1.3  -1.1 -6.4 
42 -0.3 25.2 -17.4  -8.3  -15.6 -13.5 
43 -20.7 -20.1 -43.8  -2.9  -13.1 -11.2 
44 63.4 11.4 -18.8  -1  -1.9 -2.3 
45 22.3 25.1 18.4  -1.7  -3.3 -5.6 
Table 16: Differential Cell Counts (Percentage of Total Nucleated Cells) 
Cell Type Subject 41 Subject 42 Subject 43 Subject 44 Subject 45 Mean 
Eosinophils 0.5 0.25 0.25 0.75 0.5 0.45 
Neutrophils 18 22 16 24 26 21.2 
Macrophages 80 76.5 82.25 73.25 72.5 76.9 
Lymphocytes 1.5 1.25 1.5 2.0 1.0 1.45 
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Table 17: Correlation Coefficients for Spirometry (FEV1) and Impulse Oscillometry (R5) 
Measurements of Percentages of Change from Baseline Values 
Pearson Correlation Coefficients, N = 5 
Prob > |r| under H0: Rho=0 
I1 I2 I3 S1 S2 S3
1.00000 0.44647 
0.4510 
0.37620 
0.5326 
0.46334 
0.4319 
0.69739
0.1905 
0.85817
0.0627 
0.44647 
0.4510 
1.00000 0.70794 
0.1809 
 - 0.34220 
0.5730 
0.10476
0.8669 
0.12224
0.8447 
0.37620 
0.5326 
0.70794 
0.1809 
1.00000 0.23557 
0.7029 
0.59032
0.2947 
0.43859
0.4600 
0.46334 
0.4319 
- 0.34220 
0.5730 
0.23557 
0.7029 
1.00000 0.84842
0.0692 
0.84551
0.0712 
0.69739 
0.1905 
0.10476 
0.8669 
0.59032 
0.2947 
0.84842 
0.0692 
1.00000 0.93070
0.0217 
0.85817 
0.0627 
0.12224 
0.8447 
0.43859 
0.4600 
0.84551 
0.0712 
0.93070
0.0217 
1.00000 
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Discussion
The Proposed method was designed with patient safety in mind, followed by 
efficiency of sputum sample production. 
       The first study population included ten male and ten female adult subjects. All 
subjects were  healthy (no major cardio to pulmonary conditions), non-smoking and 
between the ages of 19 to 51 years old. Participation was entirely voluntary, and subjects 
signed a informed consent before the study began. The study was undertaken in the 
Breath Laboratory  at the College of Public Health. The study was approved by IRB on 
2/17/05 # 103292. 
       Subjects filled out a Medical Questionnaire and underwent brief physical exams, 
which included chest auscultation. Health problems that were reported included Crohn 
disease, kidney stones, goiter, migraines, mononucleosis, gout, GERD, kidney transplant 
and high blood pressure. There was no wheezing noted during chest auscultations. 
       Pulmonary function monitoring during sputum induction is necessary, or safety 
reasons, to assess possible excessive bronchoconstriction due to inhalation of hypertonic 
saline43. There is no standardized protocol for pulmonary function monitoring during 
sputum induction, but many authors measure pulmonary function every 5 to 10 minutes, 
and every time symptoms occur1,2,4,66. Working Group One recommends measuring 
FEV1 at the end of each 5 minute induction interval and stop induction if there is a drop 
in FEV1 of more than 20% compared with the post to bronchodilator value or when 
adverse effects occur2. Ten minute intervals seem too long for detection of possible 
hypertonic saline inhalation caused bronchoconstriction. Long intervals might endanger 
the subject’s health. We decided to use 5 minute intervals (after each induction) for 
pulmonary function monitoring, which seems to be the safest and most rational solution.  
       Baseline FEV1 (for the first 8 subjects one measurement was obtained) and impulse 
oscillometry values which were obtained for safety reason were all in acceptable range. 
No EFV1 value was close to exclusion criteria of 60% of predicted (indicative of 
moderately severe bronchial obstruction)66. The lowest baseline FEV1 value 
measured in our study was 75.8% of predicted with subject.  
A few subjects initially had problems performing spirometry maneuvers properly, 
but with some training they improved. Later they were able to perform well. 
       Hypertonic saline inhalation causes bronchoconstriction in asthmatic subjects18. The 
actual mechanism is not well known, but may involve activation of airway mast cells or 
sensory nerve endings42. Pretreatment with short-acting beeta-2 agonist (200 microgram 
of Salbutamol) is usually recommended as the standard procedure to avoid excessive 
bronchoconstriction when studying asthmatic patients15. Before and 10 minutes after the 
bronchodilator administration, FEV1 should be measured66,67. Since we excluded 
asthmatic subjects and studied only healthy people, pretreatment with short- acting beeta-
2 agonist was not indicated for our subjects. 
        Different concentrations of saline have been used for sputum induction, which have 
ranged from 0.9% to 7%65,66 with higher concentrations being related to increased side 
effects and reduced tolerability2,67. There seems to be no difference in the cellular 
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composition of sputum induced with either isotonic or hypertonic saline; and different 
saline concentrations do not affect total and differential cell counts25. Working Group 
One recommends to use either fixed concentration of sterile saline solution (3% or 4%) or 
incremental concentrations (3%, 4% and 5%)2. We decided to utilize 3% saline in our 
method for sputum induction because of its relatively low saline concentration, which 
helps to reduce adverse effects and has shown to be effective1,2,12. Alternatively, for high 
risk subjects, the sputum induction should start with 0.9% saline solution and last for 30 
seconds, 1 minute and 5 minutes, measuring FEV1 after each induction for safety 
reason2.
       Nebulizers output varies between 0.21 to 6 ml minutes in different studies1,2,4. Some 
authors report greater sputum induction with higher nebulizer output4. Due to higher 
output of saline mist, ultrasonic nebulizers are recommended over jet nebulizers25. The 
higher success rate reported with high output ultrasonic nebulizers  prompted us to select 
DeVilbiss ultrasonic nebulizer with maximum output2,4,12. We started induction with low 
output, which was gradually increased to maximum output (6 ml per min) 
       Studies have reported that the cellular and biochemical constituents of induced 
sputum change with the duration of inhalation of hypertonic saline mist44. It was noted 
that neutrophiles and eosinophiles are prominent in early collected samples (during first 4 
minutes) and lymphocytes and macrophages predominate in later collected samples (16 
to 20 minutes)44. For most purposes, the consensus is to use a cumulative duration of 
nebulization of 15 to 20 minutes1,2. We used 4 minutes nebulization for thirteen subjects, 
8 (2x 4 min.) minutes nebulization for two subjects, and 15 (3x5 min) minutes of 
nebulization for 5 subjects. 
       Expectoration techniques and methods of subject preparation for sputum induction 
vary in different protocols1,2. Some have recommended that subjects use nose clips and 
rinse their mouth with water before induction which seems reasonable. We decided to 
adopt these precautions for our method1,2. Some subjects had difficulties keeping the nose 
clip on and complained that nose clip is uncomfortable. But after a while they got use to 
it and were able to use the proper technique. We also implemented three deep 
breath/cough procedure for sputum production, which has been effectively been used for 
some time and worked well with our subjects12. At the end of 5 minute sputum induction 
interval (continuous saline inhalation), the subject was asked to take deep breath of saline 
mist and hold it for 5 seconds followed by slow exhalation. Repeat this a total of three 
times, cover the mouth, cough deeply and spit the specimen into collection container. 
This technique seemed to facilitate sputum volume production for our subjects. 
       Some protocols utilize short sputum induction intervals (3 minutes) with cumulative 
nebulization duration of 15 to 20 minutes and report adequate sputum sample 
production12. In order to minimize possible adverse effects from hypertonic saline 
inhalation, we decided initially to induce sputum with 4 minute induction intervals. 
Nebulizer output was kept low (1 to 2 ml per min) for the first 10 seconds to prevent 
cough. Then gradually increased to maximum output (6 ml minute). A few patients 
experienced some minimal heaviness in the chest at the start of inhalation which resolved 
during the next 30 seconds.  No subject complained adverse effects nor wanted to stop for 
any reason. The procedure was tolerated well by all subjects. FEV1 and impulse 
oscillometry measurements were performed after each induction interval which 
demonstrated no FEV1 drop exceeding 20% of baseline value.
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       The first fifteen subjects underwent sputum induction with 4 minute induction 
intervals. Twelve subjects were able to produce a mean of 6.07 (4.8 to 10) ml of 
expectorate after first induction interval which contained a mean of 993 333 (360 000 to 
3 690 000) total cells per milliliter of which a mean 38% (3% to 67%) were squamous 
cells. This percentage of squamous cells is high compared to one study which had 6.3% 
(0 to 67%) of squamous cells in their healthy persons sputum sample1. One reason for 
that could be that we are studying only healthy subjects who are trying very hard to 
produce a sputum sample which may increase the proportion of squamous cells. Also, 
they do not perform the deep cough maneuver properly. One subject produced 30 ml of 
expectorate in 4 minutes which contained 380 000 total cells of which 26% were 
squamous cells. Two subjects were unable to produce adequate sputum sample in 4 
minutes which forced us to continue for another 4 minutes. They produced a mean of 
6.15 ml of expectorate which contained a mean of 750 000 total cells of which 57% were 
squamous cells. Subject 23, who had the highest percentage of squamous cells, had a 
very difficult time producing the sputum sample and performing spirometry. 
For the last five patients, we increased the induction duration to 5 minutes 
(continuous saline inhalation) with routine three sessions (15 min. of cumulative 
inhalation duration) hoping to improve cellular quality and quantity. They all tolerated 
the increased inhalation duration well without any adverse effects or complaints of 
discomfort.  The volume of the sputum sample seems to increase little with the increased 
induction time. They produced a mean of 6.19 ml (5 to 7.65 ml) of expectorate which 
contained a mean of 694 400 (360 000 to 1 100 000) total cells of which 34.3% (25% to 
57.3%) were squamous cells. In our study, the total cell count and the proportion of 
squamous cells decreased slightly with increased induction duration. Subject 37 produced 
1.5 ml of expectorate during the first 5 minutes of induction with 400 000 total cells of 
which 15% were squamous cells, 3.5 ml of expectorate during the second 5 minute 
induction with 440 000 total cells of which 82% were squamous cells, and 2.5 ml of 
expectorate during the third 5 minute induction with 240 000 total cells of which 75% 
were squamous cells.  Subject 37 actually demonstrated increased proportion of 
squamous cells in her sample after 10 minutes of induction (82%) and 15 minutes (75%) 
with reduction of total cell count. Total cell counts seem to be similar to total counts 
reported by other authors (40 000 to 4 000 000)1,6. In other studies investigators have 
obtained 10 to 16.4 ml of expectorate with 4.5% saline induction for 20 minutes from 
patients with mild to moderate asthma4.
       Some authors discard the first sample in order to reduce squamous cells 
contamination2,67. In order to reduce squamous cell contamination proper technique 
should be strictly used with enough time given for slow expectoration. Longer 
cumulative induction times (15 to 20 minutes) seem to produce less contaminated 
samples. Subjects may also try to empty the mouth of saliva first by spitting, then 
performing deep cough exercise. Selecting only dense sputum portions for processing 
would reduce salivary contamination.  
       We decided to use 5 minutes sputum induction intervals for at least three times 
minimum or until getting optimal sputum sample (5 ml) with cumulative induction 
duration of 15 to 30 minutes to increase cellularity. In our study, we were able to obtain 
about 5 to 6 ml of expectorate during initial 4 minute induction ( 13 subjects) which was 
later increased to 15 minutes (5 subjects with  three 5 minute induction intervals) in order 
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to improve cellularity. There was about 8 to 10 minutes between the induction intervals 
(continuous saline inhalation for expectoration, spirometry and impulse oscillometry 
measurements.) 
       All subjects underwent post to induction chest auscultation, which demonstrated no 
wheezing, and had no complaints of adverse effects such as chest tightness, shortness of 
breath or chest pain. Subjects were sent home in good condition, and they were reminded 
to call us if any problems should arise. 
        Preparing a sputum smear on the slide for methylene blue staining in order to 
evaluate squamous cells contamination creates some challenges.  Due to the viscosity of 
the fresh expectorate, it is quite difficult to transfer some of the sample onto the slide. It 
is close to impossible to get a homogenous layer of expectorate on the slide for 
methylene blue staining, which makes the later evaluation difficult. A sample with fewer 
than 50% of squamous cells in the field of view was considered adequate, which presents 
a quite subjective estimate and complicates the evaluation1.  Only very contaminated 
samples (81% squamous cells) were easy to identify, but slides with less (around 50%) 
squamous cell contamination (intermediate cases) were difficult to categorize to adequate 
or not adequate sample groups. We found that five samples (23, 27, 28, 37 and 26), 
which had a median of 69.5% (54% to 81%) of counted squamous cells proportions, 
demonstrated more than 50% of squamous cells per field of view after methylene staining 
and were categorized as contaminated samples. Nine samples (29, 24, 25, 31, 35, 22, 21, 
36, and 38) with a mean of counted squamous cells proportion of 36.2% (31% to 42%) 
were very hard to categorize into contaminated or not contaminated category. The 
squamous cells proportion on those slides in the field of view was around 50% and were 
categorized as undetermined. Six samples had counted squamous cells proportion mean 
of 20.7% (3% to 26%). These slides demonstrated less than 50% of squamous cells in the 
field of view and were categorized as not contaminated or adequate samples. This 
evaluation is quite subjective, but it allows us to identify grossly contaminated samples 
and is useful tool for future studies. 
We always processed our sputum samples in less than two hours of induction, as 
recommended for optimal cell counting and staining23. Dithiothreitol solution (10%) was 
always freshly prepared by adding 90 ml of distilled water to 10 ml of Sputolysin41
concentrate. Equal volume of 10% Sputalysin solution was added to preweighed entire 
expectorate for homogenization and placed in a shaking water bath for 15 minutes at 22 
degrees of Celsius periodically aspirating the sample with disposable pipette15. Mucus 
usually dissolved in about 10 to 15 minutes after which the expectorate was filtered 
through a 70 micron nylon mesh which is strongly recommended to remove debris31.
Manual total cell counting was performed using a hemocytometer. Cell viability was 
determined by the trypan blue exclusion method45. Centrifugation is required to separate 
sputum cells from the fluid phase which could be stored at  -20 to -70 degrees Celsius 
and studied later23. Centrifugation time of 5 to 10 minutes at 300 to 1500g is 
recommended45,23. In our study, we did not perform fluid phase measurements and did 
not centrifuge the expectorate.
       Initially, we followed Shandon cytocentrifuge instructions for cytospin preparations, 
which produced too thick layer of cells on the slide surface making it impossible to 
evaluate different cells. We also experimented with different centrifugation speeds and 
cell concentration until we selected optimal speed of 440 rpm for 6 minutes with 40 000 
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to 60 000 cells in cytochamber (used for the last three subjects) which gave us the 
optimal cell spread into monolayer on the slide surface23,47.
Cytospin staining was uncomplicated and fast with HEMA 3 Stain producing 
good visualization. Cytospin slides demonstrated mostly squamous cells and 
macrophages (originate from monocytes) with occasional neutrophiles and lymphocytes.  
       Correlation coefficient was calculated using SAS version 9.1 statistical software 
based on percent differences of forced expiratory volume in one second and impulse 
oscillometry values. No correlation exists between 1st induction to baseline % of change 
with r= to 0.0241 at p=0.9197, n=20. No correlation exists between 2d induction to 
baseline % of change with r= to 0.32009 at p=0.484, n=7. No correlation exist between 
3d induction to baseline % of change with r=0.39609 at p=0.5092, n=5.
       The results may be due to improper impulse oscillometry technique and small sample 
sizes. Future research should involve larger sample sizes, and impulse oscillometry 
measurements should be increased from one to three, selecting the best attempt. Proper 
technique should be followed. This area needs additional research in order to replace 
conventional spirometry with impulse oscillometry to evaluate pulmonary function. 
The second study group consisting of five healthy, non-smoking, male adults 
underwent sputum induction and processing based on F.E. Hargreave protocol which 
included inhalation of 3%, 4% and 5% saline mist for 7 minutes each. All patients 
tolerated this procedure well, except subject number 42 who had multiple episodes of 
cough, and his FEV1 dropped 13.1% after inhalation of 4% saline mist. This subject had 
his third induction done with 3% saline solution which he tolerated well and had no 
further respiratory complaints. With this protocol, we were able to obtain much higher 
total cell counts, which ranged from 1 150 000 to 6 250 000 with a mean  of 3 385 000 
compared to the proposed method. Squamous cells contamination was also much less 
ranging from 5% to 19% with a mean of 11.2% which made differential cell counting 
possible and is probably due to the fact that only dense portions of sputum were selected 
for processing. 
This method also produced good number and quality of cells from the lower 
respiratory tract, probably due to higher saline concentrations and longer induction time. 
The mean proportion of Eosinophils was 0.4%, Neutrophils 19.2%, Macrophages 
79.1% and Lymphocytes 1.3% which correlates well with the data published by other 
researchers. 
Correlation coefficient was calculated for the second study group using SAS 
version statistical software based on percent differences of forced expiratory volume in 
one second and impulse oscillometry values. There was no correlation found. 
The second method proved to be far superior compared to the proposed method in 
obtaining quality sputum sample. 
         Two methods for processing of the expectorate have evolved28. The first method 
involves selecting all denser portions from the sample with the aid of inverted 
microscope23. Using only a selected viscid sputum makes cell counting easier to perform. 
The total cell count can be expressed per gram of lower airway secretion and 
concentrations of chemicals in the fluid phase are unaffected by the influence of saliva.
Disadvantages of his method include the need for inverted microscope and longer 
processing time due to sputum selection28.
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       The second method involves processing the entire expectorate including sputum and 
saliva45. We decided to select this method to process our samples because it is quicker to 
perform. Disadvantages include the fact that the expectorate contains variable mixture of 
sputum and saliva which may dilute the sputum and confound its analysis28. Also the 
reproducibility of cell counts has been lower if squamous cell contamination exceeds 
20%46. Both methods have the same ability to distinguish asthmatics or bronchitics from 
healthy subjects, but they are not interchangeable28.
       The technical differences between those two methods are only at the very beginning 
of the processing where 100 to 1000 mg of sputum free of salivary contamination is 
selected and mixed with 10% Sputalysin solution equivalent 4 times of selected weight 
with the first method. 
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Comparison of different sputum induction protocols 
              
Study
authors
Saline
ncentrations 
lation
tion
FEV1
asurements 
bulizer
put
Expectoration
interval 
  Ref. 15 
3%, 4% and 5%, 
increased at 10 
min. intervals. 
5 min. 
periods up to 
30 min. 
Baseline and 
every 5 minutes. 
ml/min ry 5 min. 
    Ref. 8 
3%, 4% and 5%. n. each Baseline and 
every 7 minutes. 
ml/min ry 7 min. 
  Ref. 4 4.5%
5 min. 
periods up to 
20 min. 
Baseline and 
every 5 min. 
l/min 
and 2.5 
ml/min 
ry 5 min 
  Ref. 2 or 4.5% 
5 min. 
periods up 
0 min. 
Baseline and 
every 5 min. 
l/min Every 5 min. or 
they want to do 
so.
   Ref. 6 4.5%
1, 2, 4, 8, 16 
min. 
Baseline and after 
each inhalation. 
Not recorded After each 
inhalation
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Conclusions
       The proposed sputum induction protocol proved to be safe, simple and effective 
method to obtain sputum sample but was contaminated by squamous cells and did not 
produce cells from the lower airways. Sputum Induction Protocol based on F.E. 
Hargreave work was far superior producing an adequate sputum samples with cells from 
lower airways and minimal squamous cells contamination.  Study data demonstrated that 
further research is needed with larger samples in order to draw conclusions about 
correlation between impulse oscillometry and spirometry measurements. Initial 
methylene blue staining of sputum smear is a useful tool in identifying grossly 
contaminated sample by squamous cells. 
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Appendices
Appendix A:  Population Characteristics 
Subject Gender Age 
21 Male 33 
22 Female 51 
23 Female 51 
24 Male 27 
25 Male 19 
26 Male 19 
27 Male 34 
28 Male 20 
29 Male 22 
30 Female 41 
31 Male 20 
32 Female 23 
33 Male 46 
34 Female 24 
35 Male 46 
36 Female 34 
37 Female 23 
38 Female 23 
39 Female 22 
40 Female 25 
41 Male 34 
42 Male 41 
43 Male 46 
44 Male 31 
45 Male 20 
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Appendix B: Expectorate Volume Measurements (in Milliliters) 
 Group 1 Group 2 Group 3 Ungrouped 
Subject After 4 minutes After 8 minutes 
After 15 
minutes 
After 4 to 15 minutes 
21 . 6.00 . 6.00 
22 7.50 . . 7.50 
23 . 6.30 . 6.30 
24 10.00 . . 10.00 
25 7.00 . . 7.00 
26 5.00 . . 5.00 
27 5.00 . . 5.00 
28 4.80 . . 4.80 
29 4.90 . . 4.90 
30 9.00 . . 9.00 
31 5.00 . . 5.00 
32 4.90 . . 4.90 
33 30.00 . . 30.00 
34 4.80 . . 4.80 
35 4.90 . . 4.90 
36 . . 5.00 5.00 
37 . . 7.50 7.50 
38 . . 5.00 5.00 
39 . . 5.80 5.80 
40 . . 7.70 7.70 
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Appendix C: Total Cell Count 
                                                                           
Subject
Total Cell Count per 
Milliliter 
Percentage of 
Squamous Cells (%) 
21 1,100,000 33 
22 1,320,000 33 
23 310,000 81 
24 360,000 42 
25 720,000 40 
26 980,000 54 
27 450,000 67 
28 1,090,000 58 
29 690,000 42 
30 610,000 21 
31 800,000 38 
32 3,690,000 3 
33 380,000 26 
34 440,000 23 
35 770,000 35 
36 530,000 32 
37 360,000 57 
38 1,050,000 31 
39 432,000 25 
40 1,100,000 26 
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Appendix D: Spirometric Measurements (FEV1 in Litres) 
 Subject Predicted Baseline 1st Induction 2nd Induction 3rd Induction 
21 4.51 5.04 4.87 5.06 . 
22 2.67 3.23 2.89 . . 
23 2.75 3.73 3.79 3.84 . 
24 4.69 3.62 3.82 . . 
25 4.58 4.36 4.34 . . 
26 4.58 4.22 4.62 . . 
27 4.32 4.00 3.43 . . 
28 3.85 3.68 3.31 . . 
29 4.38 3.37 2.75 . . 
30 3.26 2.73 3.00 . . 
31 3.99 4.10 3.86 . . 
32 3.96 3.00 2.98 . . 
33 3.97 4.74 4.73 . . 
34 2.90 2.93 2.87 . . 
35 3.97 3.93 4.18 . . 
36 3.19 3.11 3.05 3.01 3.05 
37 3.39 3.39 3.07 3.07 3.04 
38 3.23 3.58 3.44 3.51 3.39 
39 3.33 3.07 2.90 2.92 2.90 
40 3.67 2.95 2.90 2.73 2.81 
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Appendix E: Impulse Oscillometry Measurements (R5) 
Subject Predicted Baseline 1st Induction 2nd Induction 3rd Induction 
21 2.75 3.36 3.84 4.14 . 
22 3.87 4.32 4.30 . . 
23 3.87 5.28 4.44 4.48 . 
24 2.69 2.71 3.47 . . 
25 2.60 3.62 3.64 . . 
26 2.60 4.00 3.52 . . 
27 2.76 2.46 2.15 . . 
28 2.62 2.79 3.01 . . 
29 2.63 2.85 2.82 . . 
30 3.70 8.67 9.16 . . 
31 2.61 3.46 4.37 . . 
32 2.96 4.47 3.69 . . 
33 2.90 3.66 3.94 . . 
34 3.41 5.34 4.35 . . 
35 2.90 4.07 3.73 . . 
36 3.57 5.17 4.67 4.79 5.26 
37 3.40 3.02 3.10 3.19 2.90 
38 3.40 2.73 3.16 2.82 3.16 
39 3.38 4.73 4.97 4.86 4.97 
40 3.43 4.56 4.93 5.28 4.84 
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Appendix: F Medical Questionnaire 
Subject number:
     Induced Sputum Study Medical Questionnaire 
  Date _______________________________________
1) Gender: Male    Female
2) How old are you? _____________________________
3) What is your current occupation?
_____________________________________________
4) Do you currently have, or have you ever had any of the following conditions listed
below?
YES NO CHEST PAIN, PALPITATIONS, IRREGULAR HEART
BEAT, OR HEART DISEASE?
YES NO HIGH BLOOD PRESSURE?
YES NO ASTHMA, BRONCHITIS, EMPHYSEMA, OR OTHER
LUNG OR BREATHING DISORDERS?
YES NO DIFFICULT OR HEAVY BREATHING
Appendix: F (Continued) 
YES NO A LARGE AMOUNT OF PHLEGM PRODUCTION
YES NO PREGNANCY?
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IF YOU HAVE CIRCLED YES TO ANY OF THE ABOVE QUESTIONS, PLEASE EXPLAIN:
___________________________________________________________ 
___________________________________________________________
5) Do you have any health problems or past medical history of health problems that you
have seen a physician for?
                     a._________________________________________________________ 
                     b. ________________________________________________________ 
                     c. ________________________________________________________ 
                     d. ________________________________________________________ 
                      e.________________________________________________________ 
6) Are you taking any medications?
                     a. ________________________________________________________ 
                     b. ________________________________________________________ 
                     c. ________________________________________________________ 
                     d. ________________________________________________________ 
                     e. ________________________________________________________ 
                         
                      
                         
                     
Appendix F: (continue)
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7) On what date were you last ill? _____________________________________ 
8) What did you have? illness ________________________________________
9) Do you or anybody in your family have any allergies?
Appendix F: (continue)
